Latest Stem Cells NewsRSS

16:24 EDT 23rd March 2018 | BioPortfolio

How Brain Stimulation Can Boost Memory If Paired With Learning

In 47 CE, Scribonius Largus, court physician to the Roman emperor Claudius, described in his Compositiones a method for treating chronic migraines: place torpedo fish on the scalps of patients to ease their pain with electric shocks. Largus was on the right path; our brains are comprised of electrical signals that influence how brain cells […]

Merino Sheep Provide Clue to Curly Hair

The cells on one side of each wool fiber are longer than the cells on the other, researchers find.

FDA Expands Approval Of Adcetris For Treatment Of Hodgkin Lymphoma

NewsThe FDA approved Adcetris (brentuximab vedotin) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy.

Nohla Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13032018] Prices from USD $250

SummaryNohla Therapeutics Inc Nohla Therapeutics is a biotechnology company that specializes in the development of ex vivo expanded universal donor cellular therapies for treatment of life threatening diseases. The company's lead product, hematopoietic stem and progenitor cell therapy is an ex vivo derived from umbilical cord blood. Nohla Therapeutics' products are manufactured and cryopreserved o...

Polyphor presents positive proof of concept data for innovative immuno-oncology candidate balixafortide at European Breast Cancer Conference

EQS Group-News: Polyphor AG / Key word(s): Study/Study results 23.03.2018 / 11:16 Allschwil, Switzerland, March 23rd, 2018 Polyphor presents positive proof of concept data for innovative immuno-oncology candidate balixafortide at European Breast Cancer Conference Polyphor announced today the presentation of positive data from its Phase Ib/proof of concept clinical trial for its novel ...

ATCC Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 19022018] Prices from USD $250

SummaryATCC is a nonprofit bioresource center and research organization that provides biological products, technical services and educational programs. The organization acquires, preserves, develops, authenticates, produces, and distributes standard reference microorganisms, cell lines and other materials. Its products include nucleic acids, cells and microorganisms, testing and characterization, ...

Hand Soap Ingredient Could Be Basis for Potent Antimalarial Drugs

Cheap, stable, and easily produced compounds have been the basis of antimalarial drug development for more than half a century. However, with drug resistance continuing to rise, identifying targets that impede essential metabolic pathways at multiple times during the parasite’s lifecycle is a vital approach to drug design. Now, a new study led by investigators at the University of Campinas (UNIC...

Optogenetics Used for First Time for Industrial Chemical Production

Princeton University scientists have used an optogenetics technique to control the metabolism of genetically-modified yeast and increase the output of commercially valuable chemicals. The results offer scientists a powerful new tool to probe and understand the inner working of cells, according to José L. Avalos, Ph.D.  an assistant professor of chemical and biological engineering an...

Opinion: A 3-D spinal cord atlas will improve treatment of difficult injuries

A 3-D atlas is a missing piece of the puzzle in understanding and treating difficult spinal cord injuries.

StemCell Technologies Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 14032018] Prices from USD $250

SummaryStemCell Technologies Inc StemCell is a biotechnology company that develops cell separation systems, instruments and other reagents for use in life sciences research. The company's products comprise specialized cell culture media and supplements, cell isolation products, antibodies; primary and cultured cells, mammalian cloning products, small molecules, cryopreservation media, cytokines, c...

Researchers Identify Compound That Prevents Breast Cancer Stem Cells from Activating in the Brain

Researchers at Houston Methodist used computer modeling to find an existing investigational drug compound for leukemia patients to treat triple negative breast cancer once it spreads to the brain

Novoheart Grants Options

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 03/23/18 -- Novoheart Holdings Inc. ("Novoheart" or the "Company") (TSX VENTURE: NVH)(FRANKFURT: 3NH) announced today that it has granted incentive stock options to purchase an aggregate of 693,522 common shares of the Company (the "Options") to certain directors and employees of the Company. The Options have an exercise price of $0.50 per common s...

Compound to prevent breast cancer cells from activating in brain

Researchers have used computer modeling to find an existing investigational drug compound for leukemia patients to treat triple negative breast cancer once it spreads to the brain. Images show tumor cells in a mouse brain at different days.

vTv Therapeutics Announces Completion of Phase 1b Study Evaluating TTP399 for the Treatment of Type 1 Diabetes

Simplici-T1 is an adaptive Phase 1b/2 study being conducted with support from JDRF vTv Therapeutics Inc. (Nasdaq: VTVT) today announced the completion of Phase 1b of Simplici-T1, an adaptive Phase 1b/2 study assessing the pharmacokinetics, pharmacodynamics, safety and tolerability of TTP399 in adult patients with type 1 diabetes (T1D). The study...

Biomedical Group Brings California’s Regenerative Medicine Research to the National Stage

Biocom, the association representing the life science industry of California, concluded its Regenerative Medicine Advocacy Fly-In to Washington, D.C. yesterday, the culmination of almost a year of efforts to elevate the voice of California’s regenerative medicine community. Regenerative medicine is an emerging field of research that is pioneerin...

Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia

Novartis International AG / Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. Tasigna® (nilotinib) approved for pediatric patients with newly diagnosed Ph+ CML-CP and children with Ph+ CML-CP resistant or intolerant...

20152023 World Cell Culture Products Market Research Report by Product Type, EndUser / Application and Regions / Countries [Report Updated: 21022018] Prices from USD $2800

SummaryThis report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions.Market Segment as follows:By Region / Countries North America U.S., Canada, Mexico Europe Germany, U.K., France, Italy, Russia, Spain etc South Americ...

Society for Immunotherapy of Cancer Announces 2018 Recipient of the Richard V. Smalley, MD, Memorial Award and Lectureship

The Society for Immunotherapy of Cancer (SITC) is pleased to announce Philip D. Greenberg, MD, Head of the Program in Immunology at Fred Hutchinson Cancer Research Center and University of Washington Professor of Medicine (Oncology) and Immunology, as the 2018 recipient of the Richard V. Smalley, MD, Memorial Award and Lectureship, the society’s highest honor. MILWAUKEE (PRWEB) March 22, 2018 T...

One Of Those Binary Events for AbbVie

Back in late 2015, I wrote about cancer stem cells, the idea that some tumors are driven by populations of fast-dividing stem cells. The theory has been that these are always going to be in there fighting against your efforts to kill off the downstream tumor cells, so unless you find a way to target

Triumvira Immunologics to Present at the 25th BioCentury Future Leaders Conference

Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced that it will present at the

Takeda Announces Publication of Final Data from ICLUSIG® (ponatinib) Pivotal Phase 2 PACE Trial in Blood

– Final five-year results show ICLUSIG continued to provide clinically meaningful responses, with depth and lasting duration, irrespective of dose reductions, in heavily pre-treated chronic-phase chronic myeloid leukemia patients – Takeda Pharmaceutical Company Limited (TSE: 4502) today announced tha

Third Rock Ventures Launches Rheos Medicines with $60 Million in Series A Funding to Harness Immunometabolism to Develop Precision Medicines for Immune-Mediated Diseases

Founded by luminaries in the field of immunometabolism, Rheos aims to identify mechanisms and discover medicines that tune metabolic pathways in immune cells Company’s therapeutics will focus on well-defined patient subsets in heterogeneous diseases including autoimmunity, inflammation and in immuno-oncology applications Rheos ...

BioLamina AB Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27022018] Prices from USD $250

SummaryBioLamina AB BioLamina is a biotechnology company that focuses on the development, manufacture and distribution of cell culture reagents intended for culturing primary cells. The company offers a wide portfolio of chemically defined and xenofree laminin proteins. Its product portfolio includes Laminin521, a recombinant human protein, which is the natural laminin for pluripotent stem cells; ...

Triple-Acting Aptamer–siRNA Reduces Breast Cancer Growth in Mice

Scientists at the Georgia Cancer Center have developed a chimeric anticancer molecule that simultaneously targets three key human epidermal growth factor receptors (HER) that are overexpressed in drug-resistant HER2 + breast cancers. When tested in mice carrying human breast tumors , the three-in-one aptamer–siRNA, known as H2EH3, specifically bound to the tumor cells, and interfered with HER2 a...

Gut Microbiome Promotes Pancreatic Cancer Progression

Understanding the appropriate balance of “good” bacteria within the intestinal tract has been of focus of much ongoing research for a number of years. Links between gut dysbiosis and the onset of disease are continually being established with the hope that therapeutic interventions may be developed soon to halt disease progression. Now, investigators at the NYU School of Medicine, Perlmutter C...

Quick Search


review and buy Stem Cells market research data and corporate reports here